Nianyong F. Chen

Cancer Center And State Key Laboratory Of Respiratory Health And Multimorbidity
Chengdu, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 63 publications

Correction: Granzyme B-based CAR-T cells targeting membrane-bound HSP70 suppress solid tumor growth and metastasis.

Correction: Granzyme B-based CAR-T cells targeting membrane-bound HSP70 suppress solid tumor growth and metastasis.

Journal: Oncogene
Published: July 28, 2026

First-Line Tislelizumab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Cancer: Three-Year Follow-Up of the Phase 3 RATIONALE-309 Randomized Clinical Trial.

First-Line Tislelizumab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Cancer: Three-Year Follow-Up of the Phase 3 RATIONALE-309 Randomized Clinical Trial.

Journal: JAMA oncology
Published: February 26, 2026

A Targeted Nanozyme for STING Activation Improves BiTEs Therapy Outcomes in Colorectal Cancer.

A Targeted Nanozyme for STING Activation Improves BiTEs Therapy Outcomes in Colorectal Cancer.

Journal: Small (Weinheim an der Bergstrasse, Germany)
Published: November 19, 2025

Phase Ib Trial of Finotonlimab Combined With SCT200 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.

Phase Ib Trial of Finotonlimab Combined With SCT200 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.

Journal: Cancer medicine
Published: November 10, 2025

AARS1-mediated AKR1B10 lactylation stabilizes an aerobic glycolysis-positive feedback loop to drive lenvatinib resistance in hepatocellular carcinoma.

AARS1-mediated AKR1B10 lactylation stabilizes an aerobic glycolysis-positive feedback loop to drive lenvatinib resistance in hepatocellular carcinoma.

Journal: Clinical and translational medicine
Published: August 27, 2025

Granzyme B-based CAR-T cells targeting membrane-bound HSP70 suppress solid tumor growth and metastasis.

Granzyme B-based CAR-T cells targeting membrane-bound HSP70 suppress solid tumor growth and metastasis.

Journal: Oncogene
Published: July 31, 2025

Bismuth-functionalized probiotics for enhanced antitumor radiotherapy and immune activation.

Bismuth-functionalized probiotics for enhanced antitumor radiotherapy and immune activation.

Journal: Journal of materials chemistry. B
Published: July 14, 2025

Spatiotemporal-Controlled Nanoagonists Triggered STING Activation for Cascade-Amplified Photothermal Metalloimmunotherapy.

Spatiotemporal-Controlled Nanoagonists Triggered STING Activation for Cascade-Amplified Photothermal Metalloimmunotherapy.

Journal: Biomacromolecules
Published: July 09, 2025

Unleashing the potential of bimetallic nanobomb-mediated STING pathway to enhance bispecific T-cell engager against colorectal cancer photo-immunotherapy.

Unleashing the potential of bimetallic nanobomb-mediated STING pathway to enhance bispecific T-cell engager against colorectal cancer photo-immunotherapy.

Journal: Signal transduction and targeted therapy
Published: May 18, 2025

Decomposable STING nanoagonist-amplified oncolytic virotherapy through remodeling the immunosuppressive microenvironment of triple-negative breast cancer.

Decomposable STING nanoagonist-amplified oncolytic virotherapy through remodeling the immunosuppressive microenvironment of triple-negative breast cancer.

Journal: Journal of materials chemistry. B
Published: February 21, 2025

Tumor Treatment Response-Guided Adaptive Dose De-escalation/Escalation Strategy for Concurrent Chemoradiation Therapy of Nasopharyngeal Carcinoma.

Tumor Treatment Response-Guided Adaptive Dose De-escalation/Escalation Strategy for Concurrent Chemoradiation Therapy of Nasopharyngeal Carcinoma.

Journal: International journal of radiation oncology, biology, physics
Published: February 09, 2025

Phase Ib study of SCT200 combined with paclitaxel or docetaxel in patients with recurrent or metastatic head and neck squamous cell carcinoma following platinum-based chemotherapy and PD-1 antibody.

Phase Ib study of SCT200 combined with paclitaxel or docetaxel in patients with recurrent or metastatic head and neck squamous cell carcinoma following platinum-based chemotherapy and PD-1 antibody.

Journal: Cancer letters
Published: December 11, 2024
Showing 1-12 of 63

Last Updated: 09/26/2026